DYAI
Price
$0.33Alerts
Change
-$0.02 (-5.71%)
Updated
Nov 13 closing price
Capitalization
13.61M
135 days until earnings call
Intraday BUY SELL Signals
IBIO
Price
$0.73Alerts
Change
-$0.03 (-3.95%)
Updated
Nov 13 closing price
Capitalization
47.5M
92 days until earnings call
Intraday BUY SELL Signals
Interact to see
Advertisement

DYAI vs IBIO

DYAI vs IBIO Comparison Chart in %
loading
loading
View a ticker or compare two or three
VS
DYAI vs. IBIO commentary
Nov 16, 2026

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is DYAI is a Buy and IBIO is a Buy.

Interact to see
Advertisement
SUMMARIES
A.I.Advisor
a Summary for DYAI with price predictions
Nov 13, 2026

DYAI sees its Stochastic Oscillator climbs out of oversold territory

On November 10, 2026, the Stochastic Oscillator for DYAI moved out of oversold territory and this could be a bullish sign for the stock. Traders may want to buy the stock or buy call options. Tickeron's A.I.dvisor looked at 70 instances where the indicator left the oversold zone. In 61 of the 70 cases the stock moved higher in the following days. This puts the odds of a move higher at over 87%.

Price Prediction Chart

Technical Analysis (Indicators)

Bullish Trend Analysis

The RSI Oscillator points to a transition from a downward trend to an upward trend -- in cases where DYAI's RSI Indicator exited the oversold zone, 26 of 30 resulted in an increase in price. Tickeron's analysis proposes that the odds of a continued upward trend are 87%.

The Moving Average Convergence Divergence (MACD) for DYAI just turned positive on November 09, 2026. Looking at past instances where DYAI's MACD turned positive, the stock continued to rise in 40 of 50 cases over the following month. The odds of a continued upward trend are 80%.

Following a +4.39% 3-day Advance, the price is estimated to grow further. Considering data from situations where DYAI advanced for three days, in 181 of 217 cases, the price rose further within the following month. The odds of a continued upward trend are 83%.

DYAI may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options.

Bearish Trend Analysis

The Momentum Indicator moved below the 0 level on October 12, 2026. You may want to consider selling the stock, shorting the stock, or exploring put options on DYAI as a result. In 79 of 89 cases where the Momentum Indicator fell below 0, the stock fell further within the subsequent month. The odds of a continued downward trend are 89%.

Following a 3-day decline, the stock is projected to fall further. Considering past instances where DYAI declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 86%.

The Aroon Indicator for DYAI entered a downward trend on November 13, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.

Fundamental Analysis (Ratings)

The Tickeron PE Growth Rating for this company is 7 (best 1 - 100 worst), pointing to outstanding earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.

The Tickeron Price Growth Rating for this company is 88 (best 1 - 100 worst), indicating slightly worse than average price growth. DYAI’s price grows at a lower rate over the last 12 months as compared to S&P 500 index constituents.

The Tickeron Valuation Rating of 97 (best 1 - 100 worst) indicates that the company is significantly overvalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (-5.703) is normal, around the industry mean (3.498). P/E Ratio (-1.618) is within average values for comparable stocks, (-1.193). Projected Growth (PEG Ratio) (52.360) is also within normal values, averaging (9.059). Dividend Yield (0.000) settles around the average of (130.658) among similar stocks. P/S Ratio (10.893) is also within normal values, averaging (440.869).

The Tickeron SMR rating for this company is 100 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.

The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. DYAI’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 94, placing this stock worse than average.

A.I.Advisor
a Summary for IBIO with price predictions
Nov 13, 2026

IBIO's MACD Histogram crosses above signal line

The Moving Average Convergence Divergence (MACD) for IBIO turned positive on October 27, 2026. Looking at past instances where IBIO's MACD turned positive, the stock continued to rise in 34 of 38 cases over the following month. The odds of a continued upward trend are 89%.

Price Prediction Chart

Technical Analysis (Indicators)

Bullish Trend Analysis

The RSI Indicator points to a transition from a downward trend to an upward trend -- in cases where IBIO's RSI Oscillator exited the oversold zone, 31 of 40 resulted in an increase in price. Tickeron's analysis proposes that the odds of a continued upward trend are 77%.

The Stochastic Oscillator suggests the stock price trend may be in a reversal from a downward trend to an upward trend. 48 of 61 cases where IBIO's Stochastic Oscillator exited the oversold zone resulted in an increase in price. Tickeron's analysis proposes that the odds of a continued upward trend are 79%.

Following a +8.89% 3-day Advance, the price is estimated to grow further. Considering data from situations where IBIO advanced for three days, in 186 of 223 cases, the price rose further within the following month. The odds of a continued upward trend are 83%.

IBIO may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options.

Bearish Trend Analysis

The Momentum Indicator moved below the 0 level on November 12, 2026. You may want to consider selling the stock, shorting the stock, or exploring put options on IBIO as a result. In 66 of 79 cases where the Momentum Indicator fell below 0, the stock fell further within the subsequent month. The odds of a continued downward trend are 84%.

Following a 3-day decline, the stock is projected to fall further. Considering past instances where IBIO declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 89%.

The Aroon Indicator for IBIO entered a downward trend on November 04, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.

Fundamental Analysis (Ratings)

The Tickeron PE Growth Rating for this company is 10 (best 1 - 100 worst), pointing to outstanding earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.

The Tickeron Valuation Rating of 69 (best 1 - 100 worst) indicates that the company is slightly overvalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (0.554) is normal, around the industry mean (3.498). P/E Ratio (-2.308) is within average values for comparable stocks, (-1.193). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (9.059). Dividend Yield (0.000) settles around the average of (130.658) among similar stocks. P/S Ratio (1250.000) is also within normal values, averaging (440.869).

The Tickeron Price Growth Rating for this company is 81 (best 1 - 100 worst), indicating slightly worse than average price growth. IBIO’s price grows at a lower rate over the last 12 months as compared to S&P 500 index constituents.

The Tickeron SMR rating for this company is 98 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.

The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. IBIO’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 94, placing this stock worse than average.

FUNDAMENTALS RATINGS
DYAI vs IBIO: Fundamental Ratings
DYAI
IBIO
OUTLOOK RATING
1..100
5050
VALUATION
overvalued / fair valued / undervalued
1..100
97
Overvalued
69
Overvalued
PROFIT vs RISK RATING
1..100
100100
SMR RATING
1..100
10098
PRICE GROWTH RATING
1..100
8881
P/E GROWTH RATING
1..100
710
SEASONALITY SCORE
1..100
5090

Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.

IBIO's Valuation (69) in the Biotechnology industry is in the same range as DYAI (97). This means that IBIO’s stock grew similarly to DYAI’s over the last 12 months.

IBIO's Profit vs Risk Rating (100) in the Biotechnology industry is in the same range as DYAI (100). This means that IBIO’s stock grew similarly to DYAI’s over the last 12 months.

IBIO's SMR Rating (98) in the Biotechnology industry is in the same range as DYAI (100). This means that IBIO’s stock grew similarly to DYAI’s over the last 12 months.

IBIO's Price Growth Rating (81) in the Biotechnology industry is in the same range as DYAI (88). This means that IBIO’s stock grew similarly to DYAI’s over the last 12 months.

DYAI's P/E Growth Rating (7) in the Biotechnology industry is in the same range as IBIO (10). This means that DYAI’s stock grew similarly to IBIO’s over the last 12 months.

TECHNICAL ANALYSIS
Technical Analysis
DYAIIBIO
RSI
ODDS (%)
Bullish Trend 4 days ago
87%
Bullish Trend 4 days ago
77%
Stochastic
ODDS (%)
Bullish Trend 4 days ago
87%
Bullish Trend 4 days ago
79%
Momentum
ODDS (%)
Bearish Trend 6 days ago
89%
Bearish Trend 4 days ago
84%
MACD
ODDS (%)
Bullish Trend 4 days ago
80%
Bullish Trend 4 days ago
89%
TrendWeek
ODDS (%)
Bearish Trend 4 days ago
87%
Bearish Trend 4 days ago
89%
TrendMonth
ODDS (%)
Bearish Trend 4 days ago
86%
Bearish Trend 4 days ago
89%
Advances
ODDS (%)
Bullish Trend 26 days ago
83%
Bullish Trend 8 days ago
83%
Declines
ODDS (%)
Bearish Trend 4 days ago
86%
Bearish Trend 4 days ago
89%
BollingerBands
ODDS (%)
Bullish Trend 4 days ago
83%
Bullish Trend 5 days ago
75%
Aroon
ODDS (%)
Bearish Trend 4 days ago
90%
Bearish Trend 4 days ago
90%
COMPARISON
Comparison
Nov 16, 2026
Stock price -- (DYAI: $0.33 vs. IBIO: $0.73)
Brand notoriety: DYAI and IBIO are both not notable
Both companies represent the Biotechnology industry
Current volume relative to the 65-day Moving Average: DYAI: 139% vs. IBIO: 51%
Market capitalization -- DYAI: $13.61M vs. IBIO: $47.5M
DYAI [@Biotechnology] is valued at $13.61M. IBIO’s [@Biotechnology] market capitalization is $47.5M. The market cap for tickers in the [@Biotechnology] industry ranges from $58 to $138.67B. The average market capitalization across the [@Biotechnology] industry is $2.23B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is overvalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

DYAI’s FA Score shows that 1 FA rating(s) are green while IBIO’s FA Score has 1 green FA rating(s).

  • DYAI’s FA Score: 1 green, 4 red.
  • IBIO’s FA Score: 1 green, 4 red.
According to our system of comparison, both DYAI and IBIO are a bad buy in the long-term.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

DYAI’s TA Score shows that 5 TA indicator(s) are bullish while IBIO’s TA Score has 5 bullish TA indicator(s).

  • DYAI’s TA Score: 5 bullish, 3 bearish.
  • IBIO’s TA Score: 5 bullish, 3 bearish.
According to our system of comparison, both DYAI and IBIO are a good buy in the short-term.

Price Growth

DYAI (@Biotechnology) experienced а -3.77% price change this week, while IBIO (@Biotechnology) price change was -0.93% for the same time period.

The average weekly price growth across all stocks in the @Biotechnology industry was -3.38%. For the same industry, the average monthly price growth was -5.88%, and the average quarterly price growth was -18.27%.

Reported Earning Dates

DYAI is expected to report earnings on Mar 31, 2027.

IBIO is expected to report earnings on Feb 16, 2027.

Industries' Descriptions

@Biotechnology (-3.38% weekly)

Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.

View a ticker or compare two or three
Interact to see
Advertisement

DYAI and

Correlation & Price change

A.I.dvisor tells us that DYAI and MDGL have been poorly correlated (+29% of the time) for the last year. This A.I.-generated data suggests there is low statistical probability that DYAI and MDGL's prices will move in lockstep.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To DYAI
1D Price
Change %
DYAI100%
-6.60%
MDGL - DYAI
29%
Poorly correlated
+0.51%
VRAX - DYAI
29%
Poorly correlated
-8.25%
IBIO - DYAI
27%
Poorly correlated
-4.00%
TAOX - DYAI
27%
Poorly correlated
-6.67%
AZTR - DYAI
27%
Poorly correlated
-8.99%
More

IBIO and

Correlation & Price change

A.I.dvisor indicates that over the last year, IBIO has been loosely correlated with WVE. These tickers have moved in lockstep 47% of the time. This A.I.-generated data suggests there is some statistical probability that if IBIO jumps, then WVE could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To IBIO
1D Price
Change %
IBIO100%
-4.00%
WVE - IBIO
47%
Loosely correlated
-0.79%
GPCR - IBIO
38%
Loosely correlated
+0.81%
REPL - IBIO
38%
Loosely correlated
-0.41%
EDIT - IBIO
38%
Loosely correlated
+1.40%
AVTX - IBIO
36%
Loosely correlated
+0.78%
More
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
ETFs / NAMEPrice $Chg $Chg %
MVPA36.880.44
+1.21%
Miller Value Partners Appreciation ETF (MVPA)
RSPH41.030.17
+0.42%
Invesco S&P 500 Equal Weight Health Care ETF (RSPH)
GJH9.35N/A
N/A
Synthetic Fixed-Income Sec STRATS 2004-06
APMU24.57-0.05
-0.22%
ActivePassive Intermediate Municipal Bond ETF (APMU)
FEAC32.24-0.11
-0.35%
Fidelity Enhanced U.S. All-Cap Equity ETF